Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of
Filed: 2026-08-21 AccNo: 0001104659-26-099731 Size: 644 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
On Thursday, Elutia (NASDAQ:ELUT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to
Funded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of